Cancer’s been running the table for decades, playing immune system poker with a stacked deck. CoRegen, Inc. just walked in, flipped the table, and took the dealer’s chips.
On July 9, 2025, CoRegen secured a $93 million+ private placement, a round so quietly powerful it might as well have come with silencers. No names dropped, no VC peacocking, just “select institutional and strategic backers” who understand that the loudest signal in biotech is results. And CoRegen? They’ve got those in spades. Full tumor eradication in over 400 preclinical models, triple-negative breast cancer, glioblastoma, pancreatic, prostate. No cytokine storms, no autoimmunity. Just clean kill shots and silence where tumors used to be.
It starts with the target: Steroid Receptor Coactivator-3. SRC-3 doesn’t just flip one immune checkpoint, it’s the master switchboard operator behind the scenes, throwing shade over the entire immune system. CoRegen’s tech doesn’t negotiate with tumors. It shuts SRC-3 down in Tregs using CRISPR / Cas9 and proprietary antibody-fused Cas9 biologics. That’s not checkpoint inhibition, that’s poly-checkpoint suppression. That’s a cell therapy with a plan and a platform with receipts.
The team isn’t green. Executive Chairman and CEO Steve Gorlin isn’t in this for LinkedIn likes, he’s been behind six exits north of $1B, including Medivation’s $14B takeout by Pfizer. Add Bert W. O’Malley, MD, “Father of Molecular Endocrinology,” National Medal of Science winner, SRC-3 discoverer. David C. Lonard, PhD, leading science. John C. Thomas Jr. holding the financial reins. And as of this week, Suneet Varma, former Global President of Pfizer Oncology, now serving as Chairman. That’s not a lineup, it’s a biotech mixtape with zero skips.
And the numbers? $153.3 million raised over five rounds. Post-money valuation sitting at $373.8 million. IND by Q4, first patient dosed by Q2 2026. Thirty new hires on deck. GMP buildout humming in Houston. The research runs out of Baylor College of Medicine. The business runs out of Aspen. It’s cell therapy meets mountain air with a Wall Street work ethic.
This isn’t just a play for oncology, it’s a master gene regulator platform with sights on autoimmune next. Because when you can knock out SRC-3 with 95% editing efficiency and deliver it in vivo via IV, you stop talking about cell therapy. You start talking about outpatient genetic surgery. No viral vectors, no cell factory bottlenecks. Just precision. Speed. Access.
